David Gerber

Has grant

Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences

University of Texas Southwestern Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Gerber is a Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences at The University of Texas Southwestern Medical Center. His research areas focus on oncology clinical trials, patient-provider communication regarding hepatocellular carcinoma, lung cancer risk prediction, and chemotherapy-induced peripheral neuropathy. He has published multiple articles addressing innovative treatment methods and the management of cancer-related complications, contributing significantly to the field of hematology-oncology.

Recent Grants

Grant: Close

Genetic and Phenotypic Biomarkers to Predict Immune-Related Adverse Events

Open Date: 2018-06-01

Close Date: 2021-05-31

Grant: Close

Development of New Cancer Treatments and Investigators

Open Date: 2016-05-01

Close Date: 2021-04-30

Grant: Close

A Randomized Controlled Trial (RCT) of Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System

Open Date: 2015-11-19

Close Date:

Grant: Close

Evaluating prior cancer exclusion policy to increase lung cancer trial accrual

Open Date: 2015-07-10

Close Date: 2017-06-30

Grant: Close

UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10

Open Date: 2014-04-09

Close Date: 2019-02-28

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

UNITED STATES

View details

Jennifer King

Chief Science Officer

UNITED STATES

View details

University of Texas Southwestern Medical Center

UNITED STATES

View details

Tejas Patil

Assistant Professor

University of Colorado School of Medicine

UNITED STATES

View details

Jia Wu

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Gerber

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model

Timing and Method of Patient-Provider Communication for Abnormal Hepatocellular Carcinoma Screening Results in Cirrhosis

Design and refinement of a clinical trial staffing model within the evolving landscape of oncology clinical trials

Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials

Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer

Implantable cardioverter defibrillators in people dying with cancer: A SEER‐Medicare analysis of ICD prevalence and association with aggressive end‐of‐life care

Novel and potent MICA/B antibody is therapeutically effective inKRAS LKB1mutant lung cancer models

Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

Impact of Screening on Mortality for Patients Diagnosed with Hepatocellular Carcinoma in a Safety-Net Healthcare System: An Opportunity for Addressing Disparities

Acknowledging and addressing real-world challenges to treating immune-related adverse events

Taking It to the States: Adapting Information Blocking Legislation to Oncology

Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies

Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?

Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era

Better Late Than Never: Fully Incorporating Oncology Advanced Practice Providers Into Cancer Clinical Trials

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy

21st Century Cures Act: Implementation Without Understanding Implication?

Longitudinal Experience With and Impressions of COVID-19–Related Clinical Research Changes

Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

Collaborators (14)

Jianjun Zhang

Edward Wakeland

Gao Guo

John Minna

Shaheen Khan

Jennifer King

Jorge Gomez

Chih-Yuan Hsu

Sarah Lieber

Adolfo Garcia-Sastre

Juan Manuel Carreno Quiroz

Andrew Y. Koh

Tejas Patil

Jia Wu

Make your next move.